- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Lincolnshire Today
By the People, for the People
Nexus Pharmaceuticals Launches New Cyclophosphamide Injection
The 2.5 mL and 5 mL formulations are now available for cancer treatment.
Apr. 6, 2026 at 9:02pm
Got story updates? Submit your updates here. ›
The new Cyclophosphamide Injection formulations from Nexus Pharmaceuticals offer healthcare providers more flexibility in administering chemotherapy treatments.Lincolnshire TodayNexus Pharmaceuticals, a leading pharmaceutical company, has announced the launch of its new Cyclophosphamide Injection in 2.5 mL and 5 mL formulations. Cyclophosphamide is a chemotherapy medication used to treat various types of cancer.
Why it matters
The launch of these new Cyclophosphamide Injection formulations by Nexus Pharmaceuticals provides healthcare providers with additional treatment options for cancer patients. Cyclophosphamide is a widely used chemotherapy drug, and the availability of different dosage sizes can help healthcare professionals better tailor treatment plans to individual patient needs.
The details
Cyclophosphamide Injection is an alkylating agent that interferes with the growth of cancer cells, making it an important tool in the fight against various types of cancer. The new 2.5 mL and 5 mL formulations from Nexus Pharmaceuticals offer healthcare providers more flexibility in administering the appropriate dosage to patients.
- Nexus Pharmaceuticals announced the launch of the new Cyclophosphamide Injection formulations on April 6, 2026.
The players
Nexus Pharmaceuticals
A leading pharmaceutical company that develops and manufactures a variety of medications, including the new Cyclophosphamide Injection formulations.
The takeaway
The launch of these new Cyclophosphamide Injection formulations by Nexus Pharmaceuticals provides healthcare providers with additional treatment options to better meet the needs of cancer patients, potentially improving patient outcomes.
